Product Description
Mechanisms of Action: DPD Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Fennec Pharmaceuticals
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Triple Negative Breast Cancer
Phase 1: Gastrointestinal Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| PCS6422-GI-01 | P1 |
Completed |
Gastrointestinal Cancer |
2024-06-12 |
21% |
2024-09-27 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
| PCS6422-BC-01 | P2 |
Recruiting |
Triple Negative Breast Cancer |
2026-09-01 |
12% |
2024-08-24 |
Primary Endpoints|Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
05/30/2025 |
News Article |
Processa Pharmaceuticals Announces Presentation and Publication of Three Abstracts at 2025 ASCO Annual Meeting |
|
10/30/2024 |
News Article |
Processa Pharmaceuticals Reports Third Quarter Business Highlights and Financial Results |
|
10/02/2024 |
News Article |
Processa Pharmaceuticals Announces First Patient Dosed in Phase 2 Clinical Trial of NGC-Cap in Metastatic Breast Cancer |
|
08/28/2024 |
News Article |
Processa Pharmaceuticals Provides Product Pipeline and Financial Update |
|
04/29/2021 |
PubMed |
Oral drugs in the treatment of metastatic colorectal cancer. |
|
04/13/2021 |
PubMed |
The Interaction of Porcine Dihydropyrimidine Dehydrogenase with the Chemotherapy Sensitizer: 5-Ethynyluracil. |